CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: The same authors postulated that imatinib is not a BCRP substrate, since BCRP inhibition in CML CD34+ cells neither potentiated the effect of imatinib nor affected imatinib accumulation in these cells.